Use of small molecule compounds for the manufacture of a medicament for the treatment and / or prevention of alpha-synuclein disease
By targeting and interfering with the interaction between α-synuclein and VAPB using small molecule compounds AO-365/43264238 and AG-670/40728295, the targeting and penetration problems of existing drugs in the treatment of α-synuclein diseases have been solved, achieving efficient and safe improvement of neuronal damage and disease prevention.
CN121754525BActive Publication Date: 2026-06-02CHINA REHABILITATION SCIENCE INSTITUTE (DISABILITY PREVENTION AND CONTROL RESEARCH CENTER OF CHINA DISABLED PERSONS FEDERATION)
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHINA REHABILITATION SCIENCE INSTITUTE (DISABILITY PREVENTION AND CONTROL RESEARCH CENTER OF CHINA DISABLED PERSONS FEDERATION)
- Filing Date
- 2026-03-03
- Publication Date
- 2026-06-02
Smart Images
Figure CN121754525B_ABST
Abstract
The application relates to the field of biological medicine, in particular to application of a small molecule compound in preparation of a medicine for treating and / or preventing alpha-synuclein disease, wherein the small molecule compound is at least one selected from AO-365 / 43264238 and AG-670 / 40728295. The small molecule compound provided in the embodiment of the application can precisely target and interfere with alpha-syn-VAPB interaction, improve neuron damage caused by abnormal aggregation of alpha-synuclein, thereby safely and effectively treating and / or preventing alpha-synuclein disease, in particular, Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art